Drug Information

Drug General Information
Drug ID
D0P5GE
Former ID
DAP000507
Drug Name
Dibucaine
Synonyms
Cincainum; Cinchocaine; Cinchocainum; Cincocaina; Cincocainio; Dermacaine; Dibucain; Dibucainum; Nupercainal; Nupercaine; Percamine; Sovcaine; Cinchocaine HCL; Cinchocaine hydrochloride; Cincocaina [DCIT]; Dibucaine Base; Dibucaine [USP]; Alpha-Butyloxycinchoninic acid diethylethylenediamide; Cincain (TN); Cinchocaine (INN);Cinchocainum [INN-Latin]; Cincocainio [INN-Spanish]; Dibucaine (USP); Nupercainal (TN); Nupercainal (VAN); Nupercaine (TN); Sovcaine (TN); Alpha-Butyloxycinchonic acid-gamma-diethylethylenediamine; N-[2-(Diethylamino)ethyl]-2-butoxycinchoninamide; N-(2-(Diethylamino)ethyl)-2-butoxycinchoninamide; QUINOLINE,2-BUTOXY,4-CARBOXY,(N-TRIETHYLAMINO) AMIDE CINCHOCAIN; 2-Butoxy-N-(2-(diethylamino)ethyl)cinchoninamide; 2-Butoxy-N-(beta-diethylaminoethyl)cinchoninamide; 2-Butoxy-N-(beta.-diethylaminoethyl)cinchoninamide; 2-Butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide; 2-Butoxy-N-[2-(diethylamino)ethyl]cinchoninamide; 2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide; 2-Butoxyquinoline-4-carboxylic acid diethylaminoethylamide; 2-N-Butoxy-N-(2-diethylaminoethyl)cinchoninamide; 2-butoxy-N-(2-diethylaminoethyl)quinoline-4-carboxamide; 2-butoxy-N-(alpha-diethylaminoethyl)cinchoninamide; 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide
Drug Type
Small molecular drug
Indication Anesthesia; Hemorrhoids [ICD9: 338; ICD10:R20.0, I84] Approved [538393], [542167], [551871]
Therapeutic Class
Anesthetics
Company
Novartis Pharmaceuticals Corp
Formula
C20H29N3O2
InChI
InChI=1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)
InChIKey
PUFQVTATUTYEAL-UHFFFAOYSA-N
CAS Number
CAS 85-79-0
PubChem Compound ID
3025
PubChem Substance ID
10081, 436088, 588150, 855529, 5385819, 7847798, 7978947, 8151924, 10321264, 10537030, 10589300, 11112228, 11335507, 11360746, 11363822, 11366384, 11368946, 11371487, 11374188, 11377108, 11461718, 11466104, 11467224, 11484857, 11485948, 11488817, 11490200, 11492320, 11494742, 14802538, 24893238, 29222172, 46506734, 47440166, 47515231, 47515232, 47662196, 47662197, 47736388, 47810660, 49698853, 49903695, 50100394, 50100395, 50455743, 56424123, 56436944, 57321562, 57654061, 85174672
SuperDrug ATC ID
C05AD04; D04AB02; N01BB06; S01HA06; S02DA04
SuperDrug CAS ID
cas=000085790
Target and Pathway
Target(s) Sodium channel protein type 5 subunit alpha Target Info Blocker [535573]
KEGG Pathway Adrenergic signaling in cardiomyocytes
PathWhiz Pathway Muscle/Heart Contraction
Reactome Interaction between L1 and Ankyrins
WikiPathways SIDS Susceptibility Pathways
Cardiac Progenitor Differentiation
References
Ref 538393FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 006203.
Ref 542167(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7159).
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 535573Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.